Skip to main content

Table 3 Clinical characteristics of patients with de novo metastatic NPC according to risk after PCT

From: Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein–Barr virus DNA level and tumor response to palliative chemotherapy

  Low-risk patients (n = 208) High-risk patients (n = 294)
Characteristic LRRT Non-LRRT P-value LRRT Non-LRRT P-value
Total 165 43   150 144  
Gender
 Male 134 (81.2%) 34 (79.1%) 0.828 128 (85.3%) 121 (84.0%) 0.871
 Female 31 (18.8%) 9 (20.9%)   22 (14.7%) 23 (16.0%)  
Age (years)
 ≤ 47 94 (57.0%) 19 (44.2%) 0.169 77 (51.3%) 71 (49.3%) 0.816
 > 47 71 (43.0%) 24 (55.8%)   73 (48.7%) 73 (50.7%)  
T stage
 T1 5 (3.0%) 0 (0.0%) 0.495* 6 (4.0%) 10 (6.9%) 0.458
 T2 22 (13.3%) 4 (9.3%)   22 (14.7%) 15 (10.4%)  
 T3 83 (50.3%) 20 (46.5%)   71 (47.3%) 74 (51.4%)  
 T4 55 (33.3%) 19 (44.2%)   51 (34.0%) 45 (31.3%)  
N stage
 N0 9 (5.5%) 0 (0.0%) 0.362 4 (2.7%) 3 (2.1%) 0.452*
 N1 33 (20.0%) 8 (18.6%)   29 (19.3%) 19 (13.2%)  
 N2 73 (44.2%) 18 (41.9%)   52 (34.7%) 59 (41.0%)  
 N3 50 (30.3%) 17 (39.5%)   65 (43.8%) 63 (43.8%)  
Metastatic sites
 Bone 99 (60.0%) 13 (30.2%) < 0.001* 64 (42.7%) 50 (34.7%) 0.006
 Lung 25(%15.2) 13 (30.2%)   15 (10.0%) 11 (7.6%)  
 Liver 9 (5.5%) 6 (14.0%)   14 (9.3%) 20 (13.9%)  
 Distant nodal 20 (12.1%) 0 (0.0%)   13 (8.7%) 2 (1.4%)  
 Multiple sites 12 (7.3%) 11 (25.6%)   44 (29.3%) 61 (42.4%)  
PCT regimens
 TPF 55 (33.3%) 10 (23.3%) 0.021 33 (22.0%) 32 (22.2%) 0.180
 TP 46 (27.9%) 7 (16.3%)   39 (26.0%) 29 (20.1%)  
 PF 33 (20.0%) 16 (37.2%)   40 (26.7%) 42 (29.2%)  
 GP 4 (2.4%) 4 (9.3%)   5 (3.3%) 14 (9.7%)  
 Others 27 (16.4%) 6 (14.0%)   33 (22.0%) 27 (18.8%)  
  1. Abbreviations: LRRT locoregional radiotherapy, TPF cisplatin plus docetaxel plus 5-fluorouracil, TP cisplatin plus docetaxel, PF cisplatin plus 5-fluorouracil, GP cisplatin plus gemcitabine
  2. P-value was calculated with the Pearson χ2 test or Fisher’s exact test (*)